These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 28652654)

  • 21. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
    Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
    Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
    Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
    Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
    Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation.
    Zhang Z; Lai GH; Sirica AE
    Hepatology; 2004 Apr; 39(4):1028-37. PubMed ID: 15057907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
    Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
    Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
    Jayanthan A; Hofmann B; Meier-Stephenson V; Perinpanayagam M; Dunn SE; Boklan J; Trippett TM; Truong TH; Narendran A
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):e359-e370. PubMed ID: 30702467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
    Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
    J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
    Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways.
    Viereckl MJ; Krutsinger K; Apawu A; Gu J; Cardona B; Barratt D; Han Y
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
    Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
    Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
    Jemaà M; Kifagi C; Serrano SS; Massoumi R
    Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics.
    Fan Z; Yu H; Cui N; Kong X; Liu X; Chang Y; Wu Y; Sun L; Wang G
    Exp Cell Res; 2015 Jul; 335(1):68-81. PubMed ID: 25936772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
    Brassesco MS; Pezuk JA; Salomão KB; Roberto GM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2018; 18(9):1252-1257. PubMed ID: 29493466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
    Kadletz L; Bigenzahn J; Thurnher D; Stanisz I; Erovic BM; Schneider S; Schmid R; Seemann R; Birner P; Heiduschka G
    Head Neck; 2016 Apr; 38 Suppl 1():E1918-25. PubMed ID: 26713885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.